Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross‐sectional, <scp>UK</scp> epidemiological study

DiBello, Julia; Ioannou, Christos V.; Rees, Jonathan; Challacombe, Benjamin; Maskell, Joe; Choudhury, Nurul; Kastner, Christof; Kirby, Mike

doi:10.1111/bju.13334

Cited by 37 publications

(41 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, Zoe et al reported higher PSA levels in BPH patients with MtS (23). Our findings were not in the same line with DiBello et al (22) but, were similar with results of Zou et al (23). There was higher PSA levels in Group 1 than in Group 2 without statistical significance.…”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

Preliminary assessment of neck circumference in Benign Prostatic Hyperplasia in patients with metabolic syndrome

Akın¹,

Gulmez²,

Ateş

et al. 2016

European Urology Supplements

View full text Add to dashboard Cite

ARTICLE INFO ______________________________________________________________ ______________________Objectives: To investigate the impact of neck circumference (NC) in the treatment of bening prostatic hyperplasia (BPH) patients with metabolic syndrome (MtS). Additionally, we determined dose response to alpha-blockers and cut-off values for NC and waist circumference (WC), in these patients. Materials and Methods: Non-randomized, open-labelled, and multi-centre study was conducted between March 2014 and September 2015. The BPH patients were enrolled and were divided into 2 groups: with MtS (Group 1; n=94) and without MtS (Group 2; n=103). Demographic data, anthropometric measurements, blood analyses, uroflowmetric parameters, post voiding residual urine (PVR), prostate volume, quality of life (QoL) index, NC and WC were recorded. Both groups were administered oral alphablockers and response to treatment was evaluated. Receiver-operating characteristic (ROC) curves were obtained and significant p was p<0.05. Results: In total, 197 patients were enrolled with mean age of 60.5±8.1 years. Mean NC and WC were higher in MtS patients (p<0.001). Uroflowmetry parameters and QoL indexes were comparable between groups before treatment. International prostate symptom score, uroflowmetry parameters, and QoL significant improved in Group 2 than Group 1, at 1 st and 6 th months of treatment with alpha-blockers. Success rate of treatment was significant higher in Group 2 than Group 1 (p<0.001). Cut-off values were 42.5cm and 113.5cm for NC and WC respectively, for response to alpha-blockers in BPH patients with MtS. Conclusions: MtS can be related with BPH and can negatively affect the response to alpha-blocker treatment. NC can be used for predicting response to alpha-blocker treatment in BPH patients with MtS.

show abstract

Section: Discussionsupporting

confidence: 84%

“…DiBello et al reported BPH and MtS association with elevated PSA levels and these could indirectly connect with decreased odds of having MtS and its components (22). On the other hand, Zoe et al reported higher PSA levels in BPH patients with MtS (23).…”

Section: Discussionmentioning

confidence: 99%

Preliminary assessment of neck circumference in Benign Prostatic Hyperplasia in patients with metabolic syndrome

Akın¹,

Gulmez²,

Ateş

et al. 2016

European Urology Supplements

View full text Add to dashboard Cite

show abstract

“…The prevalence of MS in this study is less than what researchers from western world [31][32][33][34] and Asia 30 found. Their studies however were conducted in the urban centres.…”

Section: Prevalence Of Metabolic Syndromecontrasting

confidence: 82%

“…14 Studies have also shown consistently that the prevalence of MS increases with age 23,27,31,32,43 Some Nigerian studies found a prevalence of between 10%-35.42% among the general populace. 18,20,21 Specifically, Ulasi et al 18 and Similayi et al 21 using IDF and ATP criteria found a prevalence of between 10.0%-23.19% in suburban centres.…”

Section: Prevalence Of Metabolic Syndromementioning

confidence: 97%

“…[17][18][19][20][21][22][23][24][25] These Nigerian authors used the WHO, IDF, and Adult Treatment Panel (ATP-III) criteria in their studies. Prevalence rates for MS in Ghana, 26 Cameroon, 27 South Africa, 28 India, 29 America, 30,31 United Kingdom 32 and Europe 33 ranged between 0% to 49.2% depending on the population studied and the criteria used. Generally, the prevalence was higher among women than men, 15-19-23-26 and with the IDF definition.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic Syndrome among Apparently Healthy Nigerians with the Harmonized Criteria: Prevalence and Concordance with the International Diabetes Federation (IDF) and Third Report of the National Cholesterol Education Programme - Adult Treatment Panel III (NCEP-ATP III) Criteria

Raimi¹,

Odusan²,

Fasanmade³

et al. 2017

JCDR

View full text Add to dashboard Cite

Background:The prevalence of metabolic syndrome varies by the definition used and the population studied. In order to make comparison among various studies possible, a new criterion which harmonizes the previous definitions was proposed. This study aims to determine the prevalence of metabolic syndrome with the harmonized criteria, and its concordance with the International Diabetes Federation (IDF), and National Cholesterol Education Programme-Adult Treatment Panel (NCEP-ATP III) criteria. Methods: One hundred and two apparently healthy individuals who participated in health screening were evaluated for metabolic syndrome. The blood pressure and anthropometric parameters were measured according to standard protocol, and fasting plasma glucose and lipid profile were determined. Metabolic syndrome was defined using the Harmonized, IDF and ATP III criteria. The agreement among the three diagnostic criteria was determined with kappa statistics. Results: The prevalence of metabolic syndrome was 4.9%, 3.9% and 4.9% with harmonized, IDF, and NCEP-ATP criteria respectively. Compared to the males, the prevalence was greater in females: Males vs Females (harmonized, 2.2% vs 7.0%; IDF, 2.2% vs 5.3%; NCEP-ATP III, 2.2% vs 7.0%). The commonest risk factor in this population was low HDL occurring in 93.0% and 37.8% of females and males respectively, followed by central obesity (50.9% in females, 13.3% in males with harmonized and IDF criteria; 33.3% in females, 4.4% in males with NCEP-ATP criteria), hypertension (12.5% in females, 18.6% in males) and hyperglycaemia (4.2% in females, 0.0% in males) in that order. None of the participants had elevated Triglyceride. There was a substantial concordance between the harmonized and the IDF (k=0.884) as well as the harmonized and NCEP-ATP III (k=1.000) definitions. Conclusion: The prevalence of metabolic syndrome was low in this population. There was a substantial agreement among the three diagnostic criteria.

show abstract

The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume

et al. 2020

View full text Add to dashboard Cite

Objective To investigate the potential mechanism of the effect of metabolic syndrome (MetS) on prostate volume (PV) and the risk of benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and the relationships of MetS and the major pathogenic factors of MetS with the clinical progression of BPH/LUTS in older Chinese men. Subjects and Methods We analyzed clinical data obtained from 506 ostensibly healthy men who underwent routine health check‐ups and recruited 415 subjects from a group of previously studied men after 4 years. We evaluated the associations of major pathological factors of MetS, including insulin resistance, subclinical inflammatory state, and sex hormone changes, with PV, the risk of BPH and the clinical progression of BPH/LUTS by using multiple linear regression and logistic regression. Results After adjustment for age, insulin, HOMA (homeostatic model assessment) index, leptin, resistin, adiponectin, C‐reactive protein, tumor necrosis factor‐α (TNF‐α), sex hormone‐binding globulin, and testosterone levels were significantly associated with PV (all P < .05), and in the age‐adjusted logistic regression model, positive associations of resistin and TNF‐α with BPH/LUTS were found (OR, 1.662, P = .007 and OR, 1.044, P < .001, respectively). Predictors of BPH/LUTS clinical progression were significantly correlated with MetS and TNF‐α. The group with higher TNF‐α levels had a higher rate of newly diagnosed BPH (9.5% vs 19.1%, P = .006) and a greater increase in PV levels (0.61 ± 0.08 vs 1.09 ± 0.35 cm3, P <.001) after 4 years. Conclusions MetS and its pathological factors were associated with an increased PV and an increased risk of BPH/LUTS that is more prone to clinical progression. TNF‐α may serve as an early biological indicator to identify which patients with BPH/LUTS are at higher risk of unfavorable outcomes.

show abstract

Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross‐sectional, UK epidemiological study

Cited by 37 publications

References 32 publications

Preliminary assessment of neck circumference in Benign Prostatic Hyperplasia in patients with metabolic syndrome

Preliminary assessment of neck circumference in Benign Prostatic Hyperplasia in patients with metabolic syndrome

Metabolic Syndrome among Apparently Healthy Nigerians with the Harmonized Criteria: Prevalence and Concordance with the International Diabetes Federation (IDF) and Third Report of the National Cholesterol Education Programme - Adult Treatment Panel III (NCEP-ATP III) Criteria

The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume

Contact Info

Product

Resources

About